What’s New with Prescription Validation Requests in 2025?

In the PAAS National® January 2025 Newsline article, PBM Prescription Validation Requests – What Are They Looking At Now? we discussed the PBM trends we saw in 2024. Below is a list of drugs reviewed and analyst comments that have been compiled through the first six months of 2025 along with a comparison from 2024. While we are not surprised that Ozempic® continues to be the top drug on the prescription validation requests, the others are not surprising either.

January-June 2025July-December 2024January-June 2024
Ozempic®Ozempic®Ozempic®
Invega®Trelegy ElliptaNurtec®
Creon®Eliquis®Mounjaro®
Zepbound®EpinephrineCreon®
Nurtec®Creon®Ubrelvy®

The top 5 comments noted by an analyst after claim review for the first half of 2025 mirror those from 2024.

Become an audit assistance member today to continue reading this article. As a member, you’ll have access to hundreds of articles and receive our monthly proactive newsletter!

  1. A clinical notation is needed and requires the following 4 elements:
    1. Date/time of the call/conversation
    2. Name and title of who you spoke with
    3. Specific details about the clarification
    4. Initials or name of the pharmacy employee making the clarification
  2. Black out acquisition cost and/or profit margin values on the backtag
  3. Document the reason for the cut quantity – auditor will want to know why the pharmacy dispensed less than what was prescribed
  4. Verify the quantity prescribed and make a clinical notation on the hard copy – Unit of Measure (UOM) is not specified or does not make sense for the medication ordered
  5. No backtag/sticker provided, typically requested by the PBM and helpful for PAAS to review the billing elements

PAAS Tips:

Jennifer Ottman, CPhT